GTHX G1 Therapeutics Inc.

G1 Therapeutics Inc is a clinical-stage biopharmaceutical company. It engages in developing novel, small-molecule therapies to target significant unmet needs to treat cancer.

As of 12/02/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/17/2017
Outstanding shares:  42,912,081
Average volume:  1,532,477
Market cap:   $251,035,674
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BF0QXG9
Valuation   (See tab for details)
PE ratio:   -1.54
PB ratio:   2.63
PS ratio:   10.39
Return on equity:   -170.88%
Net income %:   -708.20%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy